Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and ...

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...

Melius MicroBiomics receives Australian Dealings Involving Intentional Release licence as key step toward clinical evaluation: Vancouver, BC Thursday, March 19, 2026, 18:00 Hrs [I ...

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a ...

So it would seem helpful that new research on autism has just discovered a possible genetic link -- an alteration near a gene called semaphorin 5A, which is thought to guide the growth of brain-cell ...

The global preimplantation genetic testing market is growing steadily, valued at around US$ 598.4 million in 2026 and projected to reach US$ 1,081.9 million ...

Researchers from Skoltech, the International Maize and Wheat Improvement Center in Mexico, the Research Center for Cereal and ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

Researchers developed lipid nanoparticles delivering an IDO-blocking drug, and mRNA to boost immune signaling. This dual action revives exhausted T cells, eliminates tumors in models, and may enable ...

Researchers develop TRFS, a non-invasive radio frequency technique that can suppress or excite deep-brain activity to treat depression, epilepsy, and Parkinson’s.